A phase i study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies

Cancer Chemotherapy and Pharmacology

Volumn 66, Issue 6, 2010, Pages 1079-1085

  Paik, Paul K ^a   Rudin, Charles M ^b   Brown, Andrew ^a   Rizvi, Naiyer A ^a   Takebe, Naoko ^c   Travis, William ^a   James, Leonard ^a   Ginsberg, Michelle S ^a   Juergens, Rosalyn ^b   Markus, Susan ^b   Tyson, Leslie ^a   Subzwari, Sara ^a   Kris, Mark G ^a   Krug, Lee M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Obatoclax mesylate; Small cell lung cancer; Topotecan

Indexed keywords

OBATOCLAX; TOPOTECAN;

ADULT; AGED; AGITATION; ALOPECIA; AMNESIA; ANEMIA; ARTICLE; ATAXIA; BLEEDING; CARCINOID; CLINICAL ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIZZINESS; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG HYPERSENSITIVITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; EUPHORIA; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPOXIA; LIVER FUNCTION TEST; LUNG SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MERKEL CELL TUMOR; MOOD CHANGE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PAIN; PERSONALITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOSIS; RECOMMENDED DRUG DOSE; RESTLESS LEGS SYNDROME; SIDE EFFECT; SOLID TUMOR; SOMNOLENCE; SPEECH DISORDER; THROMBOCYTOPENIA; VISUAL DISORDER;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, SMALL CELL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MESYLATES; MIDDLE AGED; PATIENT SELECTION; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; RECURRENCE; TOPOTECAN;

EID: 78149410044     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1265-5     Document Type: Article

References (27)

1. W Hu JJ Kavanagh 2003 Anticancer therapy targeting the apoptotic pathway Lancet Oncol 4 721 729 1:CAS:528:DC%2BD3sXps1OgsL0%3D 10.1016/S1470-2045(03) 01277-4 14662428 (Pubitemid 37527207)
2. Adams JM, Cory S (2007) The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 26:1324-1337
3. SW Fesik 2005 Promoting apoptosis as a strategy for cancer drug discovery Nat Rev Cancer 5 876 885 1:CAS:528:DC%2BD2MXht1Witb7J 10.1038/nrc1736 16239906 (Pubitemid 41746032)
4. GeminX I (2006) Investigator's brochure GX15-070MS. Malvern, PA
5. Perez-Galan P, Roue G, Villamor N (2006) The small molecule pan-Bcl-2 inhibitor GX15-070 induces apoptosis in vitro in mantle cell lymphoma (MCL) cells and exhibits a synergistic effect in combination with the proteasome inhibitor bortezomib, AACR, pp A575
6. J Li J Viallet E Haura 2008 A small molecule pan-Bcl-2 family inhibitor, GX15-070, induces apoptosis and enhances cisplatin-induced apoptosis in non-small cell lung cancer cells Cancer Chemother Pharmacol 61 525 534 1:CAS:528:DC%2BD1cXisl2ks7k%3D 10.1007/s00280-007-0499-3 17505826 (Pubitemid 350275989)
7. JR Eckardt J von Pawel Z Papai, et al. 2006 Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer J Clin Oncol 24 2044 2051 1:CAS:528:DC%2BD28Xlt1amurs%3D 10.1200/JCO.2005.03.3332 16648504 (Pubitemid 46622113)
8. M Higashiyama O Doi K Kodama, et al. 1996 Bcl-2 oncoprotein expression is increased especially in the portion of small cell carcinoma within the combined type of small cell lung cancer Tumour Biol 17 341 344 1:STN:280: DyaK2s%2FptlertQ%3D%3D 10.1159/000217998 8938949
9. S Jiang Y Sato S Kuwao, et al. 1995 Expression of bcl-2 oncogene protein is prevalent in small cell lung carcinomas J Pathol 177 135 138 1:CAS:528:DyaK2MXpvF2htLs%3D 10.1002/path.1711770206 7490679
10. E Fokkema E de Vries H Groen, et al. 2003 Expression of apoptosis-related proteins and morphological changes in a rat tumor model of human small cell lung cancer prior to and after treatment with radiotherapy, carboplatin, or combined treatment Virchows Arch 442 349 355 1:CAS:528:DC%2BD3sXjtFKnt7s%3D 12715170
11. U Sartorius P Krammer 2002 Upregulation of bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines Int J Cancer 97 584 592 1:CAS:528:DC%2BD38XpsFWjsg%3D%3D 10.1002/ijc.10096 11807782 (Pubitemid 34087795)
12. A Ziegler GH Luedke D Fabbro, et al. 1997 Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence J Natl Cancer Inst 89 1027 1036 1:CAS:528: DyaK2sXlt1Cksrc%3D 10.1093/jnci/89.14.1027 9230884
13. U Zangemeister-Wittke T Schenker G Luedke, et al. 1998 Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines Br J Cancer 78 1035 1042 1:CAS:528:DyaK1cXntFGgsrk%3D 9792147
14. YH Kim L Girard CP Giacomini, et al. 2005 Combined microarray analysis of small cell lung cancer reveals altered apoptotic balance and distinct expression signatures of MYC family gene amplification Oncogene 25 130 138
15. AD Schimmer S O'Brien H Kantarjian, et al. 2008 A phase I study of the pan Bcl-2 family inhibitor obatoclax mesylate in patients with advanced hematologic malignancies Clin Cancer Res 14 8295 8301 1:CAS:528: DC%2BD1cXhsV2it7nO 10.1158/1078-0432.CCR-08-0999 19088047
16. R Koschel R Huber U Gatzmeier 2000 Toptecan in second-line treatment of small cell lung cancer reduced toxicity with individualized therapy Lung Cancer 20 42 10.1016/S0169-5002(00)80136-1
17. RM Huber M Reck H Gosse, et al. 2006 Efficacy of a toxicity-adjusted topotecan therapy in recurrent small cell lung cancer Eur Respir J 27 1183 1189 1:CAS:528:DC%2BD28XlvF2ht7o%3D 10.1183/09031936.06.00015605 16481389 (Pubitemid 44914302)
18. R Perez-Soler BS Glisson JS Lee, et al. 1996 Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan J Clin Oncol 14 2785 2790 1:CAS:528: DyaK28XmsFCgt7o%3D 8874340
19. SM O'Brien DF Claxton M Crump, et al. 2009 Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia Blood 113 299 305 10.1182/blood-2008-02-137943 18931344
20. C Tse AR Shoemaker J Adickes, et al. 2008 ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res 68 3421 3428 1:CAS:528: DC%2BD1cXltlSltrs%3D 10.1158/0008-5472.CAN-07-5836 18451170
21. KD Mason MR Carpinelli JI Fletcher, et al. 2007 Programmed anuclear cell death delimits platelet life span Cell 128 1173 1186 1:CAS:528: DC%2BD2sXkslGms7Y%3D 10.1016/j.cell.2007.01.037 17382885 (Pubitemid 46427871)
22. H Zhang PM Nimmer SK Tahir, et al. 2007 Bcl-2 family proteins are essential for platelet survival Cell Death Differ 14 943 951 1:CAS:528:DC%2BD2sXktlOitro%3D 10.1038/sj.cdd.4402072 17205078 (Pubitemid 46444508)
23. A Roberts W Wilson L Gandhi, et al. 2009 Ongoing phase I studies of ABT-263: Mitigating Bcl-XL induced thrombocytopenia with lead-in and continuous dosing J Clin Oncol 27 3505 abstr
24. W Wilson O O'Connor A Roberts 2009 ABT-263 activity and safety in patients with relapsed or refractory lymphoid malignancies in particular chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) J Clin Oncol 27 8574 abstr
25. M Nguyen RC Marcellus A Roulston, et al. 2007 Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis Proc Natl Acad Sci USA 104 19512 19517 1:CAS:528: DC%2BD1cXisVOgsA%3D%3D 10.1073/pnas.0709443104 18040043
26. P Hauck BH Chao J Litz, et al. 2009 Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737 Mol Cancer Ther 8 883 892 1:CAS:528:DC%2BD1MXks1amtrg%3D 10.1158/1535-7163.MCT-08- 1118 19372561
27. A Chiappori M Schreeder M Moezi 2009 A phase Ib trial of Bcl-2 inhibitor obatoclax in combination with carboplatin and etoposide for previously untreated patients with extensive-stage small cell lung cancer (ES-SCLC) J Clin Oncol 27 3576 abstr